Africa: New HIV Prevention Shot Faces Funding Hurdles in Africa

A new, long-acting injectable medicine that offers powerful protection against HIV is on the horizon for African nations, but its widespread availability hinges on overcoming significant funding and logistical challenges. This was the central theme emerging from the International AIDS Society (IAS) Conference in Kigali on Monday, July 14, 2024.

Dr. Sabin Nsanzimana, Rwanda’s Minister of Health, emphasized his country’s unwavering commitment to ending HIV/AIDS as a public health threat. “We know what we have achieved together, and we know what can be done,” he stated, highlighting new tools for prevention and treatment, and the critical need to strengthen health systems and combat stigma. Rwanda was “very pleased to have thousands of participants” at the conference, underscoring Africa’s high disease burden and the urgent need for solutions.

[caption id=“attachment_35723” align=“alignnone” width=“1000”] Dr. Sabin Nsanzimana, Minister of Health in Rwanda[/caption]

Beatriz Grinsztejn, President of the IAS, underscored the conference’s crucial timing in Africa, the continent most impacted by HIV and where funding cuts are keenly felt. She celebrated recent breakthroughs, including new WHO guidelines for long-acting HIV prevention, calling it “a testament to what’s possible when researchers, industry, global health institutions and communities work together.” Yet, she issued a stark warning “Our next challenge is clear, leaders must commit the funding and resources needed to integrate these scientific advances into health systems quickly and equitably.”

[caption id=“attachment_35726” align=“alignnone” width=“1000”] Beatriz Grinsztejn, President of the IAS[/caption]

The spotlight shone brightly on lenacapavir, a new injectable medicine that could protect individuals from HIV for several months with just one shot. The pressing question was: when will this innovative prevention reach people in African countries, and what obstacles lie ahead, especially with recent funding reductions?

Meg Doherty, a leading voice in global health discussions, offered a timeline. Following official approvals from bodies like the European Medicines Agency (EMA) and subsequent WHO qualification, the new prevention shot is expected to begin its rollout in early 2026. This initial phase will target “early adopter countries” nations already equipped to handle injectable prevention methods.

Doherty noted that a broader rollout, potentially reaching more countries, is anticipated in late 2026 or 2027 when more affordable generic versions of lenacapavir become available.

[caption id=“attachment_35725” align=“alignnone” width=“876”] Meg Doherty[/caption]

However, getting this transformative medicine to everyone who needs it will not be simple. Doherty outlined several critical challenges:

System Setup; Ensuring robust supply chains to deliver the medicine reliably, and training healthcare workers to administer the injections and counsel patients effectively. Building Demand; Generating awareness and interest among communities so that people actively seek out and access this new prevention option and Impact of Funding Cuts; A major concern is how recent funding reductions will affect clinics. Many health facilities, including HIV clinics, sexual health clinics, and those serving key populations, have been impacted.

The conference, therefore, served as a powerful call to action. While scientific innovation offers a clear path forward in the fight against HIV, its success in Africa will ultimately depend on sustained investment, strong logistical frameworks, and a determined commitment to equitable access.

African Updates